|Day's range||25.86 - 26.00|
Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death
Johnson & Johnson Chief Scientific Officer Dr. Paul Stoffels predicts the most vulnerable will begin to receive vaccines within 12 months to prevent COVID-19.
Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.
Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough
AstraZeneca (AZN)/Merck's (MRK) study evaluating cediranib added to Lynparza fails to meet the primary endpoint of PFS in patients with platinum-sensitive relapsed ovarian cancer
Update on Phase 3 GY004 for Cediranib and LYNPARZA® (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
Merck KGaA said core earnings would see "strong" growth in 2020 when adjusted for one-offs and currency swings, but it would have to revise goals if the coronavirus outbreak does not start to ease from next month. "Should the crisis grow or trigger a global recession, the company would adapt its business forecast," it said in a statement.
Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research Discover Novel Class of Candidate Anti Malaria Agents
KEYTRUDA® Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Classical Hodgkin Lymphoma (cHL)
(Bloomberg) -- Palantir Technologies Inc. scored another win in Washington Tuesday, securing a contract worth as much as $823 million to provide software to the Department of Defense, according to communications reviewed by Bloomberg.The four-year deal represents more than a decade of work by the Palo Alto, California-based data mining startup to break into the club of existing defense contractors, and bolsters the company’s prospects as it prepares it to go public.The contract is the second half of a larger project. Palantir and Raytheon Co. won the first half of the deal in 2018, worth $876 million. This second part involves Palantir working with BAE Systems to replace the U.S. Army’s Distributed Common Ground System, used for aggregating and analyzing data, which has faced technical challenges. Palantir sued the Army in 2016 to win the right to compete for the new contract after the U.S. Government Accountability Office determined the old system was underperforming and over budget. It is unclear how revenue from the contract will be split between Palantir and BAE Systems. The deal will increase annual sales at Palantir’s government division from its current $500 million or so, according to people familiar with Palantir’s finances who asked not to be identified discussing private information. Investor Peter Thiel co-founded Palantir in 2004, and the company’s software has been used for controversial ends like enabling the immigration deportation policies championed by President Trump, as well as for philanthropic ones like preventing sex trafficking and finding missing children.About half of Palantir’s business relies on deals with large corporate customers like Merck KGaA and Airbus SE, which use the software to manage drug discovery and improve supply chain logistics.The company is exploring both an IPO and a direct listing, but does not yet have a target date for going public, Bloomberg has reported. To contact the author of this story: Lizette Chapman in San Francisco at email@example.comTo contact the editor responsible for this story: Anne VanderMey at firstname.lastname@example.org, Alistair BarrFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.
Merck Receives Complete Response Letter from the US FDA for Supplemental Biologics License Applications (sBLAs) for KEYTRUDA Six-Week Dosing Schedule
ERVEBO® (Ebola Zaire Vaccine, Live) Now Registered in Four African Countries, Within 90 Days of Reference Country Approval and WHO Prequalification
Merck’s KEYTRUDA in Combination with Chemotherapy Met Primary Endpoint of PFS as First-Line Treatment for Metastatic Triple-Negative Breast Cancer
The yearly results for Merck & Co., Inc. (NYSE:MRK) were released last week, making it a good time to revisit its...